Skip to main content
. 2024 Nov 7;17:17562848241293643. doi: 10.1177/17562848241293643

Figure 5.

Figure 5.

Change in heart rate from baseline to week 2 in patients receiving etrasimod 2 mg OD with Dizziness TEAEs on days 1–3 (a) without Bradycardia and (b) following discontinuation due to Bradycardia in the Placebo-controlled UC cohort.

aFor patient 1, post-dose timing of day 2 measurements was unknown. Day 2 measurements shown are the last measurements available from that day.

bpm, beats per minute; TEAE, treatment-emergent adverse event; UC, ulcerative colitis.